Denosumab in osteoarthritis: from mechanism to clinical translation
Jiaoniu Duan, Gailian Zhang, Liyun Zhang · 2026
Read Denosumab in osteoarthritis: from mechanism to clinical translation by Jiaoniu Duan, Gailian Zhang, Liyun Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13243102.txt.
Description
Jiaoniu Duan and two co-authors set out a 2026 opinion piece on denosumab, a bone drug, as a possible treatment for osteoarthritis. The joint disease affects more than 600 million people, yet no approved drug can slow or change its course. Care still starts late, eases pain for a time, and often ends in joint replacement.
The authors trace how the drug blocks RANKL, a signal that drives bone breakdown and joint inflammation in lab work. They weigh early signs from hand and knee studies and ask who should get the drug and at what dose. They also ask how stopping treatment should be handled. Their plan for future trials gives clinicians a clear map of the proof that is still missing.
Catalog record
| CREATOR | Jiaoniu Duan, Gailian Zhang, Liyun Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |